Core Viewpoint - The Chinese medical beauty industry is transitioning from chaotic growth to a more regulated, rational, and value-focused era [1][11] Group 1: Industry Dynamics - The era of upstream medical beauty suppliers relying solely on price control to maintain high profits is likely over, as evidenced by recent collaborations between New Oxygen and 14 upstream manufacturers [2] - The pricing power dynamics within the industry are shifting, with New Oxygen gaining leverage to negotiate prices due to its expanding network of stores [7] - The rapid development of the medical beauty industry has led to improved policy approval efficiency, resulting in a significant increase in the number of approved products [9] Group 2: Pricing Strategies - New Oxygen's founder, Jin Xing, aims to lower the prices of medical beauty projects, challenging the traditional high-price system that has persisted in the industry [3] - The introduction of New Oxygen's "Miracle Youth Needle" project at a price of 4,999 yuan per unit significantly undercuts the established market price, leading to backlash from suppliers [4] - The company has continued to innovate with pricing strategies, launching further iterations of its youth needle products at even lower prices, such as 2,999 yuan and 999 yuan [4] Group 3: Supplier Relationships - Despite previous conflicts, some brands that had publicly opposed New Oxygen have recently reconciled and entered into partnerships, indicating a shift in industry relationships [5] - New Oxygen's purchasing volume has reached significant levels, with some suppliers relying on the company for a substantial portion of their sales, fostering stable partnerships [9] Group 4: Future Outlook - The medical beauty industry is moving towards a model that emphasizes value over price competition, as the previous pricing wars have disrupted the long-standing pricing power of upstream manufacturers [10] - New Oxygen plans to expand its store presence significantly in key cities, aiming for a total of at least 35 new stores in 2026 [8] - The company remains optimistic about the future, believing that increased supply and improved technology will lead to more affordable services for consumers [8]

行 业 研 究 / 医 药 生 物 / 证 券 研 究 报 医药生物行业周报 《药品管理法实施条例》全面修订，推 动医药产业创新与监管升级 2026 年 02 月 03 日 【行情回顾】 【本周观点】 【风险提示】 医药行业政策风险；研发进展不及预期风险；业绩不及预期风险 挖掘价值 投资成长 强于大市（维持） 东方财富证券研究所 证券分析师：何玮 证书编号：S1160517110001 证券分析师：崔晓倩 《医药零售高质量发展政策发布，行业有 望加速整合利好龙头》 2026.01.27 《J.P. Morgan 健康大会召开，中国创新药 企扬帆出海》 2026.01.20 《聚焦脑机接口与小核酸药物，JPM 盛会 前奏下医疗布局新浪潮》 2026.01.14 《创新浪潮涌动下，医药板块修复与突破 之路》 证书编号：S1160525080001 相对指数表现 -10% 0% 10% 20% 30% 40% 2025/2 2025/8 2026/2 医药生物 沪深300 相关研究 2025.12.15 《医药生物行业 2025 年三季报财报总结： 业绩分化，医疗设备板块显现拐点》 2025.11.13 告 本周( ...

Core Viewpoint - The collaboration between medical beauty brands and "villains" signifies a shift in brand communication, aiming to inject confidence and vitality into the traditionally anxiety-ridden medical beauty marketing landscape [4][6]. Group 1: Industry Overview - The medical beauty industry in China has been characterized by a scarcity of quality and affordable services, leading to information asymmetry and regulatory gray areas that complicate consumer decision-making [9][10]. - Traditional medical beauty institutions often struggle with scalability, as many have been operating for over twenty years with limited store counts, typically between 20 to 40 [6][10]. - The industry is transitioning from a seller's market to a buyer's market due to an increase in product approvals, which is expected to enhance competition and reduce product scarcity [11][12]. Group 2: Company Development - New Oxygen has opened 50 direct-operated clinics across 16 cities and completed over 1 million treatments, positioning itself as a leader in the light medical beauty chain brand sector in China [5][4]. - The company has established the "Youth Selection Alliance," which sets stringent standards for product quality and aims to redefine what constitutes a "good product" in the market [15][16]. - New Oxygen's approach includes a focus on building a scalable and high-quality delivery system to address the industry's challenges of trust and efficiency [7][12]. Group 3: Supply Chain and Market Dynamics - The "Youth Selection Alliance" allows New Oxygen to leverage its treatment volume to negotiate better terms with suppliers, ensuring high-quality products are available to consumers [16][18]. - The company has formed partnerships with major pharmaceutical and medical beauty suppliers, significantly increasing its purchasing power and market influence [17][18]. - New Oxygen's strategy emphasizes the importance of a robust supply chain and efficient distribution channels, which are critical for driving down costs and enhancing product availability [20][21]. Group 4: Future Outlook - The transformation within the medical beauty industry is expected to lead to a healthier ecosystem and a more rational consumer market, characterized by increased choice, transparency, and trust [27][28]. - As the industry moves towards full market competition, companies that can effectively balance consumer trust and supply chain efficiency will thrive [27][28]. - New Oxygen's ongoing efforts to integrate technology and streamline operations are essential for overcoming existing industry challenges and achieving sustainable growth [22][28].

Core Viewpoint - Recently, the new specifications of the polylactic acid facial filler (commonly known as "youthful needle") developed by Sihuan Pharmaceutical's Meiyan Space have been officially approved by the National Medical Products Administration, further enriching the aesthetic medicine product pipeline [1] Group 1: Company Strengths - Sihuan Pharmaceutical is positioned as a leading player in China's aesthetic medicine industry, leveraging a comprehensive product matrix to create a competitive barrier, a robust channel network to solidify market foundations, and a revenue scale that outpaces the industry [1][10] - The company has established a full-category product layout, being the first in the industry to cover five core categories, thus creating a strong product barrier [4] - The company has a nationwide coverage of nearly 8,000 aesthetic medicine institutions and has established deep partnerships with over 230 leading groups and regional core institutions, showcasing a resilient "direct + agency" channel model [5] Group 2: Financial Performance - In the first half of 2025, Sihuan Pharmaceutical's aesthetic medicine business achieved revenue of 580 million yuan, representing a year-on-year growth of 81.3%, demonstrating its leading position in the industry [7][13] - The company has completed 35 dividend distributions since its listing, with a total dividend amount exceeding 7.8 billion yuan, alongside nearly 3.9 billion yuan in cash reserves, indicating a favorable low valuation, high growth, and high dividend profile [13] Group 3: Research and Development - Sihuan Pharmaceutical is increasing its investment in R&D within the aesthetic medicine sector, with plans to launch three significant Class III medical devices in 2025, including the youthful needle and the girl needle, which are expected to support future revenue growth [8] Group 4: Brand and Compliance - The company adheres to GMP standards in product development and production, enhancing its brand's academic attributes through hosting academic conferences and training for doctors, thereby strengthening its professional brand image [9]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 公司名稱: 四環醫藥控股集團有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00460 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,00 ...

Core Insights - Company is accelerating its scale operations by collaborating with 14 upstream suppliers and plans to open 35 new offline stores in the coming year, transitioning from an online medical beauty platform to a physical medical institution with a low-price model [1][6][7] Group 1: Strategic Partnerships - The establishment of the "Youth Selection Alliance" with 14 upstream suppliers aims to achieve mutual growth through price linkage, tiered supply, training collaboration, and product traceability [3] - This partnership indicates an improvement in the pricing issues that previously strained relationships with suppliers, allowing for a more stable collaboration [3][5] - Notable suppliers in this alliance include Allergan, Medimime, and others, which have previously raised concerns over pricing discrepancies with the company [3][4] Group 2: Pricing Strategy - The company has consistently aimed to lower the prices of its products, such as the "童颜针" (youthful needle), which saw significant price reductions over the years, making it more accessible to consumers [4][6] - The low-price strategy is seen as a way to attract new consumers, although the long-term sustainability of this approach will depend on product effectiveness and perceived value [4][5] Group 3: Operational Expansion - As of now, the company has established 50 stores across 16 cities, with plans to add at least 35 more stores by the end of 2026, aiming for a total of 500 doctors and 1000 nursing staff [7] - The company is entering a strategic transformation phase, focusing on improving operational gross margins while maintaining its scale advantage [7][8] Group 4: Financial Performance - The company reported a total revenue of 1.063 billion yuan for the first three quarters of 2025, a decrease of 3.17% year-on-year, with a loss of 133 million yuan [8][9] - The beauty treatment services segment has become the largest revenue source, contributing 427 million yuan, a significant increase of 385.05% year-on-year, accounting for 40.16% of total revenue [9] - The goal for 2026 includes achieving quarterly profitability while enhancing gross margins through a diverse product offering [8][9]

Core Insights - The domestic medical beauty industry is undergoing a structural transformation in 2025, shifting from a "seller's market" to a "buyer's market" due to an increase in the supply of upstream products [1] - The approval of 52 new Class III medical device registrations in 2025 indicates a significant change in the supply-demand relationship within the industry [1] - Upstream manufacturers are compelled to adjust their competitive strategies, focusing on technological innovation, product iteration speed, and commercialization capabilities [1][4] Upstream Manufacturers - The competition among upstream manufacturers is intensifying as the medical beauty market continues to expand and diversify, with the industry size surpassing 300 billion yuan [3] - The light medical beauty market is expected to grow at a compound annual growth rate of over 20% in the next five years, becoming the mainstream segment [3] - Hyaluronic acid, botulinum toxin, collagen, and regenerative materials are projected to dominate the injection materials market in 2024, with respective market shares of 36%, 29%, 19%, and 16% [3] Product Supply Expansion - In 2025, 25 new Class III medical device registrations for hyaluronic acid products were approved, alongside approvals for collagen products, youth needles, and new materials like agarose and calcium phosphate [4] - Manufacturers are shifting from a "follow the trend" model to focusing on product innovation and expanding new indications, particularly in women's health-related aesthetics [4][5] Competitive Landscape - The competition is expected to transition from merely obtaining licenses to a focus on core technology, research efficiency, and understanding end-user needs [5] - The relationship between upstream manufacturers and downstream medical beauty institutions is evolving into a mutually beneficial partnership rather than a zero-sum game [6] Downstream Institutions - The approval of 52 new Class III medical device registrations has provided downstream institutions with greater product selection and negotiating power with upstream manufacturers [6] - New Oxygen's introduction of competitively priced products has sparked controversy among upstream manufacturers, highlighting the ongoing price competition in the market [6] Market Dynamics - Public hospitals are increasingly entering the medical beauty sector, with 203 hospitals opening or establishing medical beauty departments in 2025, a 229% increase from the previous year [8] - Major internet platforms like Meituan and Tmall are leveraging their traffic advantages to enhance the medical beauty sector, intensifying market competition [8] - The future of the medical beauty industry is expected to be characterized by a diverse and competitive landscape, where trust and professional credibility are crucial for consumer acceptance [8]

Core Insights - New Oxygen announced multiple strategic initiatives, including the establishment of the Youth Selection Alliance with 14 upstream manufacturers and a strategic partnership with Sota [1][4] - The company received several prestigious certifications from Euromonitor International, including recognition for having the largest number of light medical beauty chain stores [5] Group 1: Strategic Initiatives - The Youth Selection Alliance aims to achieve win-win outcomes for upstream companies and consumers through collaboration in areas such as price-volume linkage, tiered supply, training, and product traceability [5] - New Oxygen's partnership with Sota includes a guarantee for the traceability of each Thermage treatment head, with a compensation policy for non-compliant equipment [5] Group 2: Supply Chain and Expansion - Since 2021, New Oxygen has invested 1 billion yuan in building its supply chain system, establishing 9 medical device sales companies and a network of 1 central warehouse and 8 forward warehouses across the country [5] - As of January 8, 2026, New Oxygen's clinics have achieved a cumulative treatment volume of 1 million across 50 stores in 16 cities [5] Group 3: Future Plans - The company plans to continue its conservative product selection strategy and launch multiple new products in the fields of phototherapy, water light, large injections, and health by 2026 [6] - New Oxygen aims to accelerate its offline expansion and recruitment of medical staff, with plans to add 35 new stores and increase the number of doctors to 500 and nursing staff to 1000 by the end of 2026 [6]

Core Viewpoint - The CEO of New Oxygen Group, Jin Xing, stated that the friction with upstream suppliers has not significantly impacted the company's business, despite some suppliers expressing concerns about the company's pricing strategy and product sourcing [1][2][6]. Group 1: Pricing Strategy and Market Impact - In September 2025, New Oxygen launched the "Youth Needle" product priced at 2999 yuan, which is significantly lower than the market price of over 10,000 yuan, disrupting the existing pricing structure of upstream manufacturers [1][6]. - Despite backlash from several upstream manufacturers, including claims of unauthorized product sourcing and training issues, sales of the "Youth Needle" reportedly surged in October, November, and December 2025, indicating strong consumer acceptance [2][6][7]. Group 2: Business Expansion and Partnerships - As of January 8, 2026, New Oxygen has established 50 clinics across 16 cities and achieved a cumulative treatment volume of 1 million [3][6]. - New Oxygen announced the formation of the "Youth Premium Alliance" with 14 upstream manufacturers, aiming to enhance collaboration through price-volume linkage, tiered supply, training, and product traceability [3][6]. Group 3: Industry Dynamics and Future Outlook - The medical beauty industry is experiencing a shift towards a buyer's market, with an increasing number of suppliers providing more options for medical institutions, which can now select long-term partners and customize products based on their needs [4][7]. - The industry has seen a significant increase in the issuance of medical device certifications, with 52 Class III medical device certificates issued in 2025, suggesting a growing supply landscape [4][7].

Market Overview - US stock markets rebounded collectively, with Hong Kong stocks jumping 1.35%, pushing the Hang Seng Index above 27,000 points [1] - Gold prices surpassed $5,000 for the first time, with a monthly increase expected to be the largest in 40 years [1] - Zijin Mining and Zijin Gold International announced a cash acquisition of all issued shares of Golden Joint for approximately CAD 5.5 billion (around RMB 28 billion or USD 4 billion) [1][2] Company Insights - Golden Joint, a Canadian gold mining company, has significant assets including the Sadiola gold mine and the Côte d'Ivoire gold complex, with gold resources of 533 tons and production forecasts of 10.7 tons in 2023 and 11.1 tons in 2024 [2] - Zijin Gold International's stock rose nearly 11% in January, with a cumulative increase of 70% for the month [2] Insurance Sector - A significant amount of household deposits will mature this year, leading to increased demand for wealth management products, particularly participating insurance policies [3] - Major insurance companies like China Life and AIA saw stock increases of over 5% and 3% respectively due to this demand [3] Technology Sector - Semiconductor companies are experiencing price increases, with companies like Huahong Semiconductor reaching new highs [4] - IC design companies are also expected to raise prices, with MediaTek and Analog Devices indicating price adjustments [4] - Tencent's AI assistant "Yuanbao" launched a new social AI feature, which is expected to stimulate cloud business growth [4] Aviation Industry - COMAC's C919 aircraft has completed assembly and is entering the delivery process, aiming for a delivery rate of one aircraft every 10 to 15 days, with a target of at least 28 aircraft for the year [6] - The domestic production rate of C919 has increased from 10% to an expected 70% by 2026, with the European Aviation Safety Agency starting flight test evaluations [6] Semiconductor Industry - Semiconductor company SMIC reported a revenue of RMB 17.162 billion for Q3 2025, a year-on-year increase of 9.95%, with a net profit of RMB 1.517 billion, up 43.15% year-on-year [8] - The company is experiencing increased capacity utilization and expects a price increase in wafer foundry services in 2026 [9] - SMIC's average sales price for wafers increased by 3.8% due to a shift in product mix and increased demand [8][9]